Weekly Roundup: July 12-16

Author(s):

ICYMI, some of this week’s featured content includes practice management tips, SGT-510 for psoriasis, July skin care, plus more.

POLL: Are you or your employer requiring employees to be vaccinated?

The Mainstream Patient: July 12, 2021

This week’s edition of The Mainstream Patient features stories about eyelid eczema, biologics, jojoba oil for acne, plus more.

Racial and Ethnic Variation in Acne

A study in the Journal of Drugs in Dermatology gathered a panel of skin of color experts to examine acne treatment in patients with skin of color.

A Guide to ABM’s “The Evolution of Aesthetics” Symposium

With in-person conferences coming out of the shadows and into the light once again, we detail a guide to Aesthetics Biomedical’s “Perspectives. The Evolution of Aesthetics” symposium happening July 24.

Study Investigates Who Treats Patients with Injectables

The Dermatologic Surgery journal published a study on who performs cosmetic injections at dermatology and plastic surgery practices.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of July.

Dupilumab Demonstrates Long-Term Safety for Moderate to Severe AD

The fully human monoclonal antibody is currently approved in more than 60 countries.

Non-Steroidal Immunosuppressants for AD May Not Impact Dupilumab Treatment

Patients on placebo with a history of systemic non-steroidal immunosuppressants generally fared worse than their treatment-naïve counterparts.

Analysis: Discrepancies Between ‘Atopic Dermatitis’ and ‘Eczema’

Investigators show that both terms tend to be used in different contexts within the biomedical literature.

Celebrating One Year of The Cutaneous Connection Podcast

July marks the 1 year anniversary since the launch of The Cutaneous Connection Podcast. Check out what episodes were the most popular here.

Sol-Gel Announces New Data for SGT-510 for Psoriasis

Sol-Gel has announced pre-clinical data on SGT-510, its roflumilast drug, for the treatment of psoriasis.

Belapectin, Pembrolizumab Show Early Activity, Tolerability in Metastatic Melanoma

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma.

10 Tips to Jump Start Your Practice Post-COVID-19

Looking to get your practice ahead of the rest post-COVID-19? These 10 practical practice management tips will help you jump start your practice into the future.